Alzheimer's Biomarkers: Overview of existing and future biomarkers (by LabCE)

1.5 P.A.C.E. contact hour(s)

(based on 151 customer ratings)

Author: David J Moffa, PhD, BCLD
Reviewers: Kevin F. Foley, PhD, DABCC, MT, SC, TC(NRCC); Jenny Camele, MT(ASCP)

Course provided by LabCE.

This course describes Alzheimer’s Disease (AD) and reviews the latest facts and statistics. Upon completion of this course, the user will understand the signs, symptoms, and stages of AD and describe Alzheimer’s causes, risk factors and prevention. A summary of the current methods used to diagnose AD is presented, along with the role of genetics in AD. The key AD biomarkers and their availability in CSF and Blood are discussed as well as the current commercially-available biomarker tests and treatments for AD.

See more courses in: Molecular Pathology

Included In These Course Packages

Continuing Education Credits

P.A.C.E.® Contact Hours (acceptable for AMT, ASCP, and state recertification): 1.5 hour(s)
Course number 578-017-20, approved through 2/28/2022
Florida Board of Clinical Laboratory Personnel Credit Hours - General (Molecular Pathology): 1.5 hour(s)
Course number 20-767462, approved through 9/1/2020

Objectives

  • Describe Alzheimer’s Disease (AD) and review the latest facts and statistics.
  • Understand the signs, symptoms and stages of AD.
  • Describe Alzheimer’s causes, risk factors and prevention.
  • Summarize the current methods used to diagnose AD.
  • Explain the role of genetics in AD and describe risk genes and deterministic genes.
  • Describe the key AD biomarkers and their availability in CSF and Blood.
  • Review the current commercially-available biomarker tests for AD.
  • Discuss the current treatments for AD.

Customer Ratings

(based on 151 customer ratings)

Users Also Bought

12 P.A.C.E.® contact hours
(1 ratings) $44 Add to cart
1 P.A.C.E.® contact hour
(429 ratings) $20 Add to cart
13.5 P.A.C.E.® contact hours
(12 ratings) $44 Add to cart
2 P.A.C.E.® contact hours
(4 ratings) $15 Add to cart

Course Outline

  • Alzheimer's Disease (AD): Overview
      • Definition, Facts, and Statistics
      • Signs, Symptoms, and Stages
      • Causes, Risk Factors, and Prevention
      • Causes, Risk Factors, and Prevention (Continued)
  • Diagnosis of Alzheimer’s Disease (AD):
      • Overview and Diagnostic Approaches
      • Overview and Diagnostic Approaches (Continued)
  • Genetics of AD
      • Risk Genes and Deterministic Genes
      • Risk Genes and Deterministic Genes (Continued)
      • Summary on Genetic Testing for AD
  • Alzheimer's Disease (AD) Biomarkers
      • AD Biomarkers: Overview
      • AD Biomarkers: Key Biomarkers
      • AD Biomarkers: Key Biomarkers (Continued)
      • AD Biomarkers: Key Biomarkers (Continued)
      • AD Biomarkers: Key Biomarkers (Continued)
      • CSF or Blood Biomarkers for AD?
  • Commercially-available Biomarker Tests for AD Assessment
      • Quest Diagnostic’s Beta-Amyloid 42/40 Ratio and Apolipoprotein E (APOE) Isoform Panel:
      • LabCorp’s APOE Alzheimer’s Risk Test:
      • Athena Diagnostic’s ADmark Alzheimer’s Evaluation
  • Conclusions on Biomarker Tests for AD Assessment
      • Conclusions on Biomarker Tests for AD Assessment:
      • Conclusions on Biomarker Tests for AD Assessment: Recommendations
  • Treatment of Alzheimer's Disease (AD)
      • Treatment Overview
      • Alzheimer's Drugs
      • Other Treatments
  • References
      • References

Additional Information

Level of instruction: Intermediate

Intended audience: Clinical laboratory professionals including medical laboratory scientists, medical technologists, and technicians. This course is also appropriate for clinical laboratory science and MLT students, pathologists, and clinicians.

Author information: David J. Moffa, PhD, BCLD, has over 30 years of experience in the healthcare industry as an executive manager, clinical laboratory director, and medical laboratory scientist. He is currently a technical consultant for Kentmere Healthcare, Wilmington, DE, and until his retirement, was the Regional Director for LabCorp, Inc. He holds a PhD in medical biochemistry from the School of Medicine, West Virginia University.

Reviewer information: Kevin F. Foley, PhD, DABCC, MT, SC is the director of clinical pathology for the Kaiser Permanente Northwest region. He also teaches clinical chemistry at Oregon Health Sciences University. Dr. Foley earned his PhD in clinical pharmacology and toxicology at East Carolina School of Medicine in North Carolina.

Reviewer information: Prior to her retirement in 2012, Jenny Camele was employed by Laboratory Corporation of America as the manager of customer service operations for the Fairmont West Virginia Region and a Quality Assurance committee member. She holds a Bachelor of Science degree in Medical Technology from West Virginia University.

How to Subscribe
MLS & MLT Comprehensive CE Package (by LabCE)
Package of 122 online courses$95
Add to cart
Single online course$20
Add to cart
  • Order for instant access through any computer, any browser.
  • No shipping, faxing, or waiting for certificates.
  • Print or save your certificate of completion as soon as you've completed the course.
  • You'll have 90 days to complete your purchased courses.
Course provided by LabCE.
Structure of Amyloid Beta
This file is licensed under the Creative Commons Attribution-Share Alike 3.0 Unported license. You are free: 
•	to share – to copy, distribute and transmit the work
•	to remix – to adapt the work


A depiction of a healthy brain vs. a severe Alzheimer’s brain.  By the final stage of Alzheimer’s Disease, the brain tissue shrinks significantly. 
(Abnormal deposits of proteins form amyloid plaques and tau tangles throughout the brain. Once-healthy neurons stop functioning, lose connections with


IRS-1 Structure


Tau and P-Tau Protein



 
ASCLS CE's design and platform are provided by MediaLab, Inc.